(Q41348057)

29 September 2017

1 reference

title

Multiple myeloma: prognosis and standard treatment (English)

1 reference

29 September 2017

Oken MM

1

1 reference

29 September 2017

1 January 1997

1 reference

29 September 2017

1 reference

29 September 2017

15

1 reference

29 September 2017

57-64

1 reference

29 September 2017

1

1 reference

Serum β 2-microglobulin in myelomatosis: potential value in stratification and monitoring

29 September 2017

1 reference

https://api.crossref.org/works/10.3109%2F07357909709018918

Long-term prognostic value of serum beta 2 microglobulin in myelomatosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909709018918

Ras oncogene mutation in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909709018918

Evaluation of serum deoxythymidine kinase as a marker in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909709018918

High serum lactate dehydrogenase level as a marker for drug resistance and short survival in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909709018918

Improved survival times in multiple myeloma treated with melphalan, prednisone, cyclophosphamide, vincristine and BCNU: M-2 protocol

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909709018918

Standard treatment of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909709018918

Combined chemotherapy with ABCM versus melphalan for treatment of myelomatosis. The Medical Research Council Working Party for Leukaemia in Adults

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909709018918

Initial treatment in multiple myeloma: no advantage of multidrug chemotherapy over melphalan-prednisone. The Myeloma Group of Western Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909709018918

The Chemotherapy of Plasma-Cell Myeloma and the Incidence of Acute Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909709018918

Induction and maintenance therapy in multiple myeloma: a multicenter trial of MP versus VCMP.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909709018918

VAD-based regimens as primary treatment for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909709018918

Interferon therapy in myelomatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909709018918

Interferon in the Treatment of Refractory Multiple Myeloma: An Eastern Cooperative Oncology Group Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909709018918

Complete remission induction with combined VBMCP chemotherapy and interferon (rIFN alpha 2b) in patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F07357909709018918

10.3109/07357909709018918

21 January 2018

Identifiers

DOI

1 reference

29 September 2017

1 reference

PubMed ID

9028391